*Medical Weight Management: A Multidisciplinary Approach DOI: http://dx.doi.org/10.5772/intechopen.105475*

weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. International Journal of Obesity. 2005;**2013**(37):1443-1451

[104] Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: Key elements of the step trials 1 to 5. Obesity Silver Spring Md. 2020;**28**:1050-1061

[105] Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine. 2021;**384**:989

[106] Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The step 4 randomized clinical trial. Journal of the American Medical Association. 2021;**325**:1414-1425

[107] Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: An endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism. 2015;**100**:342-362

[108] Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. American Diabetes Association. 2004;**27**:155-161

[109] Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes, Obesity & Metabolism. 2009;**11**:361-371

[110] Kushner RF. Weight loss strategies for treatment of obesity. Progress in Cardiovascular Diseases. 2014;**56**:465-472

[111] Son JW, Kim S. Comprehensive review of current and upcoming anti-obesity drugs. Diabetes and Metabolism Journal. 2020;**44**:802-818

[112] Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/ topiramate in severely obese adults: A randomized controlled trial (EQUIP). Obesity Silver Spring Md. 2012;**20**:330-342

[113] Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlledrelease phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study. The American Journal of Clinical Nutrition. 2012;**95**:297-308

[114] Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2010;**376**:595-605

[115] Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustainedrelease combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. American Diabetes Association. 2013;**36**:4022-4029
